Microbial (Pro)TGase

Recombinant microbial (bacterial) transglutaminase


(MTG, recombinantly produced in E. coli, gene derived from Streptomyces mobaraensis)

Order
Quantity
Price
Status
25 U 270 € available
250 U (1 vial) 2140 € available
10 x 25 U 2140 € available
500 U (1 vial) 3750 € available
20 x 25 U 3750 € available


Documents
Art. No. T001
Synonym EC 2.3.2.13, MTG, Protein-glutamine-γ-glutamyltransferase
Background info Transglutaminases are a family of enzymes that catalyze the posttranslational modification of proteins by inserting an isopeptide bond within or between polypeptide chains. These
enzymes catalyze the acyl transfer reaction between the γ-carboxyamide groups of peptidebound glutamine residues and a variety of primary amines, particularly the ε-amino group of lysine. The resulting crosslink is of great significance, since it is highly stable and also resistant to mechanical and proteolytic degradation.

Microbial Transglutaminase by Zedira
Molecular Weight 38,333 Da (Dispase-activated MTG with N-terminal sequence: FRAPDSDDR...)
Source Recombinantly produced in E. coli.
No material of animal origin is used within production process. Gene derived from Streptomyces mobaraensis.
Purity > 95 % (SDS-PAGE)
Specific Activity > 25 U/mg [One unit will catalyse the formation of 1 μmole of hydroxamate per min from Z-Gln-Gly-OH and hydroxylamine at pH 6.0 at 37°C, Grossowicz et al. (1950)]
Appearance White lyophilized solid.
Reagents The purified transglutaminase is lyophilized from 50 mM NaOAc pH 5.0 + 0.3 M NaCl.
Reconstitution Add the volume of H2O the protein is lyophilized from (see Certificate of Analysis) to the vial of lyophilized powder. Rotate vial gently until solid dissolves.
Reconstituted MTG solution might be turbid. However, MTG activity is not affected. In this case, centrifuge the solution and collect the supernatant.
After reconstitution, the solution should be stored frozen in working aliquots.
Application Labeling, immobilisation, conjugation and modification of proteins.
MTG can tolerate up to 10% DMSO in aqueous solutions without significant influence on its catalytic activity. A small activity loss of 4% was observed in the presence of 20% DMSO.
Storage Store at –20°C in working aliquots. Repeated freezing and thawing is not recommended.
Delivery is possible at ambient temperature.
Reference(s)

Grossowicz et al., J. Biol. Chem. 1950, 187, 111-25
Ando et al., Agric. Biol. Chem. 1989, 53, 2613-17
Pasternack et al., Eur. J. Biochem. 1998, 257, 570-6
Pfleiderer et al., Microbiol. Res. 2005, 160, 265-71
Jeger et al., Angew. Chem. Int. Ed. Engl. 2010, 49, 9995-7
Kaufmann et al., Food Addit. Contam Part. A 2012, 29, 1364-73
Dennler et al., Bioconjugate Chem. 2014, 25, 569-78
Dennler et al., Chembiochem. 2015, 16:861-7

Note INTENDED FOR RESEARCH USE ONLY, NOT FOR USE IN HUMAN, THERAPEUTIC OR DIAGNOSTIC APPLICATIONS.

Products

  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.

News  

  • Zedira publication: Microbial Transglutaminase Used in Bread Preparation at Standard Bakery Concentrations Does Not Increase Immunodetectable Amounts of Deamidated Gliadin
  • Pressemitteilung: Dr. Falk Pharma und Zedira geben den Abschluss der Phase 1b-Studie für ZED1227 zur Zöliakie-Therapie bekannt und planen Start der Wirksamkeitsstudie
  • Press release: Dr. Falk Pharma and Zedira announce completion of phase 1b clinical trial of ZED1227 for the treatment of celiac disease and move on to proof of concept study
  • Press Release: Dr. Falk Pharma GmbH and Zedira enter a phase 1b clinical trial for a celiac disease drug
  • Zedira publication: Microbial transglutaminase has a lower deamidation preference than human tissue transglutaminase on a celiac disease relevant wheat gliadin T-cell epitope
  • Press release: Additional subsidy funding for clinical development of a celiac disease drug
  • Pressemitteilung: Zusätzliche Fördermittel für die klinische Entwicklung eines Zöliakie-Medikamentes
  • Press Release: Cooperation between Zedira and Cardiff University - Transglutaminase 6 is the focus of new research into ataxia
  • Press Release: Dr. Falk Pharma and Zedira enter phase I clinical trials for a celiac disease drug
  • Press release: Zedira receives further funding to develop Factor XIIIa-blockers for safe anticoagulation

Blog  

Events  

  • MEDICA

    13.11.2017 - 16.11.2017
    Düsseldorf, Germany

  • Gordon Research Conference on: Transglutaminases in Human Disease Processes

    16.06.2018 - 17.06.2018
    Les Diablerets, Switzerland